CDTX
Income statement / Annual
Last year (2024), Cidara Therapeutics, Inc.'s total revenue was $1.28 M,
a decrease of 98.00% from the previous year.
In 2024, Cidara Therapeutics, Inc.'s net income was -$169.83 M.
See Cidara Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.28 M |
$63.91 M |
$64.29 M |
$49.57 M |
$12.07 M |
$20.92 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$84.88 M
|
$1.52 M
|
$143,000.00
|
$189,000.00
|
$68.02 M
|
$46.40 M
|
$523,000.00
|
$667,000.00
|
$732,000.00
|
$461,000.00
|
| Gross Profit |
-$83.61 M
|
$62.38 M
|
$64.15 M
|
$49.38 M
|
-$55.95 M
|
-$25.49 M
|
-$523,000.00
|
-$667,000.00
|
-$732,000.00
|
-$461,000.00
|
| Gross Profit Ratio |
-65.57
|
0.98
|
1
|
1
|
-4.64
|
-1.22
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$71.88 M
|
$68.53 M
|
$75.52 M
|
$73.09 M
|
$68.02 M
|
$46.40 M
|
$49.14 M
|
$42.82 M
|
$35.70 M
|
$23.48 M
|
| General & Administrative Expenses |
$20.62 M
|
$18.33 M
|
$18.49 M
|
$18.74 M
|
$15.90 M
|
$16.24 M
|
$14.14 M
|
$12.90 M
|
$12.74 M
|
$8.84 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$20.62 M
|
$18.33 M
|
$18.49 M
|
$18.74 M
|
$15.90 M
|
$16.24 M
|
$14.14 M
|
$12.90 M
|
$12.74 M
|
$8.84 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$211,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$92.49 M
|
$86.87 M
|
$94.01 M
|
$91.83 M
|
$83.92 M
|
$62.64 M
|
$63.29 M
|
$55.72 M
|
$48.44 M
|
$32.31 M
|
| Cost And Expenses |
$177.38 M
|
$88.39 M
|
$94.01 M
|
$91.83 M
|
$83.92 M
|
$62.64 M
|
$63.29 M
|
$55.72 M
|
$48.44 M
|
$32.31 M
|
| Interest Income |
$5.81 M
|
$2.00 M
|
$191,000.00
|
$212,000.00
|
$262,000.00
|
$221,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$191,000.00
|
$212,000.00
|
$262,000.00
|
$221,000.00
|
$629,000.00
|
$7,000.00
|
$271,000.00
|
$120,000.00
|
| Depreciation & Amortization |
$0.00
|
$118,000.00
|
$143,000.00
|
$189,000.00
|
$286,000.00
|
$328,000.00
|
$523,000.00
|
$667,000.00
|
$732,000.00
|
$461,000.00
|
| EBITDA |
-$176.10 M |
-$24.37 M |
-$33.36 M |
-$42.26 M |
-$71.56 M |
-$41.40 M |
-$62.76 M |
-$55.72 M |
-$47.70 M |
-$31.85 M |
| EBITDA Ratio |
-138.12
|
-0.38
|
-0.46
|
-0.85
|
-5.94
|
-2.01
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-138.12
|
-0.38
|
-0.46
|
-0.85
|
-5.95
|
-1.99
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.81 M
|
$2.00 M
|
$191,000.00
|
-$212,000.00
|
-$262,000.00
|
$632,000.00
|
$4.27 M
|
-$7,000.00
|
$271,000.00
|
$120,000.00
|
| Income Before Tax |
-$170.29 M
|
-$22.49 M
|
-$29.53 M
|
-$42.47 M
|
-$72.11 M
|
-$41.09 M
|
-$59.02 M
|
-$55.73 M
|
-$48.17 M
|
-$32.19 M
|
| Income Before Tax Ratio |
-133.56
|
-0.35
|
-0.46
|
-0.86
|
-5.98
|
-1.96
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$443,000.00
|
$272,000.00
|
$1.44 M
|
$262,000.00
|
-$1.01 M
|
$4.27 M
|
-$667,000.00
|
-$732,000.00
|
-$461,000.00
|
| Net Income |
-$169.83 M
|
-$22.93 M
|
-$29.80 M
|
-$43.91 M
|
-$72.37 M
|
-$40.09 M
|
-$59.02 M
|
-$55.73 M
|
-$48.17 M
|
-$32.19 M
|
| Net Income Ratio |
-133.2
|
-0.36
|
-0.46
|
-0.89
|
-6
|
-1.92
|
0
|
0
|
0
|
0
|
| EPS |
-26.82 |
-5.25 |
-8.53 |
-16.75 |
-34.83 |
-26.78 |
-45.62 |
-63.69 |
-66.49 |
-46.76 |
| EPS Diluted |
-26.82 |
-5.25 |
-8.53 |
-16.74 |
-34.83 |
-26.78 |
-45.62 |
-63.69 |
-66.49 |
-46.76 |
| Weighted Average Shares Out |
$6.35 M
|
$4.37 M
|
$3.49 M
|
$2.62 M
|
$2.08 M
|
$1.50 M
|
$1.29 M
|
$875,043.00
|
$724,449.00
|
$688,484.00
|
| Weighted Average Shares Out Diluted |
$6.35 M
|
$4.37 M
|
$3.49 M
|
$2.62 M
|
$2.08 M
|
$1.50 M
|
$1.29 M
|
$875,043.00
|
$724,449.00
|
$688,484.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
